Last edition
News about "Antisense oligonucleotide"
GSK Reports Positive Phase 3 Results for Bepirovirsen in Chronic Hepatitis B Treatment
GSK’s investigational antisense oligonucleotide bepirovirsen demonstrated statistically significant functional cure rates in chronic hepatitis B patients, offering a potential alternative to lifelong antiviral therapy.
Antisense Oligonucleotide | 29/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members